Spots Global Cancer Trial Database for Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors

Official Title: Phase 2 Study Evaluating the Efficacy of Epoetin Beta (Neocormon®) For Fatigue and Quality of Life of Patients Receiving Palliative Care for a Solid Malignant Tumor

Study ID: NCT00559195

Conditions

Anemia

Fatigue

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

epoetin beta

quality-of-life assessment

Study Description

Brief Summary: RATIONALE: Epoetin beta may cause the body to make more red blood cells and may help relieve fatigue in patients with malignant solid tumors receiving palliative care. PURPOSE: This phase II trial is studying how well epoetin beta works in treating fatigue and anemia in patients receiving palliative care for malignant solid tumors.

Detailed Description: OBJECTIVES: Primary * Evaluate the impact of epoetin beta on fatigue and quality of life of patients receiving palliative care for malignant solid tumors. Secondary * Evaluate the impact of epoetin beta on hemoglobin level (increase \> 2 g/dL). OUTLINE: Patients receive epoetin beta subcutaneously once a week for up to 3 months. Fatigue, quality of life, and hemoglobin and reticulocyte levels are assessed every 4 weeks.